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Abstract: Extracellular matrix remodeling within the tumor microenvironment has been recognized
as a relevant dynamic framework during tumor growth. However, research on proteases that trigger
this remodeling keeps revealing a wide range of actions including both pro- and anti-tumorigenic.
The extracellular protease ADAMTS1 exemplifies this dual role. In this work, we first confirmed
a positive correlation of ADAMTS1 with endothelial-like phenotype of human melanoma cells
together with the finding of associated signatures, including key genes such as endothelial CDH5.
Using a CRISPR-Cas9 approach, we observed that the inhibition of ADAMTS1 in an aggressive
uveal melanoma model compromised its endothelial-like properties, and more importantly, caused a
robust blockade on the progression of tumor xenografts. Although vasculature emerged affected
in ADAMTS1-deficient tumors, the most relevant action implied the downregulation of endothelial
CDH5 in tumor cells, in association with stemness markers. Indeed, melanoma sphere assays also
revealed a deficient commitment to form spheres in the absence of ADAMTS1, directly correlating
with stemness markers and, remarkably, also with CDH5. Finally, taking advantage of advanced
bioinformatics tools and available public data of uveal melanomas, we disclosed new prognosis
factors, including endothelial elements and ADAMTS proteases. Our findings support the key role of
ADAMTS proteases for uveal melanoma development since earlier stages, modulating the complex
crosstalk between extracellular matrix and the induction of stemness and endothelial-like features.
To our knowledge, this is the first report that supports the development of therapeutic targets on the
extracellular matrix to overcome uveal melanoma.
Keywords: ADAMTS; cancer stem cell; endothelial-like phenotype; extracellular matrix;
vasculogenic mimicry
1. Introduction
The tumor microenvironment (TME) has been highlighted as a key player during tumor
development, providing specific signals that support cell invasion, proliferation and phenotypic
plasticity [1]. TME is extremely dynamic, involving all its cellular and extracellular constituents, and its
full understanding still requires a multilayered research to identify new targets and biomarkers [2].
On the extracellular side, the actions of a variety of proteases contributed to such dynamism by the
alteration of multiple pathways with impact during all stages of neoplasias. In fact, proteolytic activity
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has been widely acknowledged in different tumor types [3]. Among these proteases, studies on
ADAMTS1, first member of the ADAMTS (A Disintegrin And Metalloprotease with ThromboSpondin
motifs) family [4], underlined its tumor suppressive [5,6] but also its protumorigenic properties [7–9],
including its key contribution for the acquisition of an endothelial-like (EL) phenotype [10] or its
competences to modulate the immune response [11]. Likewise, similar attributes have been reported
to further ADAMTS members [12], recognizing the necessary commitment to know better the nature
of ADAMTS-mediated actions that concern the modulation of phenotypic properties of cancer cells.
The influence of extracellular matrix (ECM) remodeling on plasticity and stemness capacities
of cancer cells is still an open query. For example, the study of vasculogenic mimicry (VM) [13]
revealed an alternative mechanism of neovascularization where tumor cells revert to a stem-like
state, favoring the acquisition of an EL phenotype [14]. Although few reports have described the
contribution of metalloproteases cooperating with ECM factors during this phenomenon [15], ECM
remodeling needs to be thoroughly considered, as physical and chemical properties affect cancer
plasticity [16]. VM was firstly reported on melanoma cases but many questions remain regarding
the relationship between stemness, cancer plasticity and EL phenotype. We now add new insights
about the contribution of ECM regulatory molecules in a human uveal melanoma (UVM) setting.
Very significantly, although UVM is classified as a rare cancer, it is very aggressive with up to 50%
of the patients developing metastasis [17]. Indeed, UVM plasticity has been previously uncovered
including the relevant regulation of microenvironment-related pathways [18].
Here, we first demonstrated an in vitro EL phenotype for various melanoma cell lines that
correlated with ADAMTS1 expression, and we also unveiled common gene signatures with endothelial
lineages. Moreover, the inhibition of ADAMTS1 affected in vitro EL attributes and, more importantly,
caused a major halt of tumor progression in mice with alterations in vascular and endothelial parameters.
We also observed a significant compromise of stemness features in tumor cells, emphasized by our
melanoma sphere assays. Finally, taking advantage of advanced bioinformatics tools and available
TCGA data on UVM, we disclosed new prognosis elements that sustained our experimental data.
To our knowledge, this is the first study reporting the activity of an extracellular protease on the
development of UVM by the induction of stemness and endothelial-like features, and it prompts the
development of new strategies to fight this fatal malignancy.
2. Results
2.1. ADAMTS1 Expression Correlates with An Endothelial-Like Phenotype of Melanoma Cells
We used the well-established Matrigel assay [19] to characterize the endothelial-like (EL) phenotype
of melanoma cells. While MUM-2B, SK-MEL-28, SK-MEL-103, SK-MEL-147 and C8161 generated clear
endothelial-like networks in Matrigel, MUM-2C, A-375 and G-361 formed cell clusters (Figure 1a).
Accordingly, we classified these lines as EL+ and EL− cell lines, respectively. We evaluated ADAMTS1
gene expression in all cell lines (Figure 1b and Figure S1a), observing that its expression was significantly
higher in EL+ cell lines compared with EL− ones (Figure 1c).
Taking into account the public availability of gene expression data of these cell lines, we executed
an in silico comparison of their gene signatures including also human umbilical vein endothelial cells
(HUVECs) to ponder their EL related phenotype (Figure 1d and Table S2). We obtained 467 genes with
a significantly different expression between EL+ (including HUVECs) and EL− cells: 47 upregulated
and 420 downregulated (Figure 1d and Table S3a). Interestingly, within the upregulated group we
found relevant endothelial-related genes (e.g., CDH5 [VE-cadherin], TFPI and THBD), which were also
linked with ECM remodeling (e.g., NID1) in our models. Indeed, GO enrichment analysis revealed a
prevalence of pathways strongly related with vascular functionality, such as regulation of coagulation,
hemostasis, wound healing and ECM organization (Figure 1e and Table S3b), including some of the
genes mentioned above. Overall, these results encourage additional studies of the EL phenotype of
our melanoma cells and the contribution of ADAMTS1.
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Figure 1. Endothelial-like properties of melanoma cells and correlation with ADAMTS1 expression. 
(a) Representative images of 3D Matrigel-based assay of human melanoma cell lines, 24 h after 
seeding. 20,000 cells/well were cultured for MUM-2B, SK-MEL-147, C8161, MUM-2C and SK-MEL-
103; and 30,000 cells/well for SK-MEL-28, G-361 and A-375 (white scale bar = 500 µm); (b) Graph 
representing mRNA fold change expression of ADAMTS1 in human melanoma cell lines. Values are 
relative to MUM-2B (n = 21 for MUM-2B, n = 17 for MUM-2C, n = 11 for A-375, n = 5 for C8161 and 
SK-MEL-28, n = 6 for G-361, n = 15 for SK-MEL-103 and n = 9 for SK-MEL-147). EL+ and EL- 
phenotypes are indicated; (c) Graph representing mRNA fold change expression of ADAMTS1 in 
Figure 1. Endothelial-like properties of melanoma cells and correlation with ADAMTS1 expression.
(a) Representative images of 3D Matrigel-based assay of human melanoma cell lines, 24 h after seeding.
20,000 cells/well were cultured for MUM-2B, SK-MEL-147, C8161, MUM-2C and SK-MEL-103; and
30,000 cells/well for SK-MEL-28, G-361 and A-375 (white scale bar = 500 µm); (b) Graph representing
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mRNA fold change expression of ADAMTS1 in human melanoma cell lines. Values are relative
to MUM-2B (n = 21 for MUM-2B, n = 17 for MUM-2C, n = 11 for A-375, n = 5 for C8161 and
SK-MEL-28, n = 6 for G-361, n = 15 for SK-MEL-103 and n = 9 for SK-MEL-147). EL+ and EL−
phenotypes are indicated; (c) Graph representing mRNA fold change expression of ADAMTS1 in
human melanoma cell lines, according to their EL+ or EL− phenotype (values are based in same data
that Figure 1C); (d) Heatmap showing differential gene expression between EL+ (including HUVECs)
and EL− cell lines. Only significant differently expressed genes are depicted (47 upregulated and
420 downregulated, FDR < 0.05). Gene Expression Omnibus (GEO) ID samples are listed and color
coded in Table S2; (e) Representation of top ten GO Biological Processes after enrichment analysis using
significantly upregulated genes in EL+ cells. Red line determined the limit of significance: -log (0.05).
(****, p < 0.0001; ***, p < 0.001; and **, p < 0.01).
2.2. ADAMTS1 Inhibition Affects In Vitro Endothelial-Like Phenotypic Properties and Endothelial-Related
Signature
We evaluated if the inhibition of ADAMTS1 altered EL+ phenotypic plasticity in uveal MUM-2B
cells, using CRISPR-Cas9 technology. Once confirmed ADAMTS1 edition and inhibition in two
different MUM-2B clones by Sanger sequencing (Figure S1b) and Western blot (Figure 2a and Figure
S1c), we studied their EL phenotype performing in vitro Matrigel assays (Figure 2b). We evaluated
the resulting structures with the non-biased WimTube tool. Using different cell culture densities,
we confirmed that ADAMTS1 inhibition diminished the number of tubes, branching points and loops
(Figure 2b and Figure S1d).
Following these findings, we then wondered if the impairment of the EL phenotype in MUM-2B
ADAMTS1-knock out (ATS1-KO) cells was also reflected on their endothelial-related signature.
We compared the expression levels of recognized endothelial-related genes that are relevant for the VM
phenomenon: CDH5 (also found in our global analysis showed above), ENG, EPHA2, KDR (VEGFR2),
LAMC2, TEK and TIE1 [20,21]. Remarkably, these analyses revealed a significant downregulation
of CDH5, KDR and TIE1 in MUM-2B ATS1-KO cells (Figure 2c and Figure S1e). We approached a
similar study with EL+ C8161 cells, also confirming a significant downregulation of CDH5 in their
respective C8161 ATS1-KO (Figure 2d and Figure S1f). These results indicated that ADAMTS1 exerts a
key contribution to EL plasticity in melanoma cells, as its inhibition affected in vitro EL phenotype
and downregulated endothelial-related genes, particularly CDH5, again highlighting the relevance of
this gene.
Next, we approached an in vivo tumor model to shed light on the role of ADAMTS1 in UVM
plasticity and tumorigenesis.
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Figure 2. ADAMTS1 inhibition affects in vitro endothelial-like phenotypic properties and endothelial-
related signature. (a) Western blot analysis of conditioned media and cell lysates of ADAMTS1 in 
MUM-2B WT and ATS1-KO cells. Black arrows point full-length (FL) ADAMTS1. Red Ponceau 
staining and Actin were used as loading controls for conditioned media and cell lysates, respectively 
(uncut blots including a densitometry analysis are shown in Figure S1c); (b) Representative images 
(original and WimTube filtered) of Matrigel assay for MUM-2B WT and ATS1-KO cells, 24 h after 
seeding 20,000 cells/well. Scatter plots represent the parameters resulting of WimTube analysis: total 
tubes, total branching points and total loops (n = 12 for all groups, white scale bar = 500 µm); (c) 
Graphs representing mRNA fold change expression of CDH5, ENG, EPHA2, KDR, LAMC2, TEK and 
TIE1 in MUM-2B WT and ATS1-KO cells (n = 3–5 for WT, n = 3–6 for ATS1-KO1 and n = 2–4 for ATS1-
KO2); (d) Graph representing mRNA fold change expression of CDH5 in C8161 WT and ATS1-KO 
cells (n = 4 for all groups). (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; and *, p < 0.05. WT cells were used 
as control for statistical analyses). 
2.3. ADAMTS1 Inhibition Affects in vivo Tumor Progression and Vasculature 
According to previous reports with MUM-2B cells [9], we first executed xenograft studies using 
Swiss Nude (SwN) mice. Very significantly, all SwN mice injected with WT but none with ATS1-KO 
cells developed tumors, corroborated even after sacrifice (Figures 3a-b and d). Although this robust 
result already implied a key contribution of ADAMTS1, we applied the following conditions to 
confirm it. We injected cells in a 1:1 PBS:Matrigel solution (SwN-Matrigel), reported to support initial 
cell engraftment and subsequent tumor progression [22]. Under these conditions, ATS1-KO cells, 
although inducing some tumors, still displayed lower efficiency than WT cells (Figure 3a). Indeed, 
progression of ATS1-KO-derived tumors was clearly compromised in comparison with WT group 
(Figures 3b-d). 
Given the major blockade of tumor growth when ADAMTS1 was inhibited in these two models, 
we were unable to get relevant biopsies of some experimental groups. Therefore, we pursued tumor 
Figure 2. DAMTS1 inhibition affects in vitro endothelial-like phenotypic properties and
endothelial-related signature. (a) Western blot analysis of conditioned media and cell lysates of
ADAMTS1 in MUM-2B WT and ATS1-KO cells. Black arrows point full-length (FL) ADAMTS1.
Red Ponceau staining and Actin were used as l ading controls for conditio ed media and cell lysates,
respectively (u c t blots including a densitometry analysis are shown in Figure S1c); (b) Representative
ima es (original and WimTub filtered) of Matrigel assay for MUM-2B WT and ATS1-KO cells, 24 h
aft r seeding 20,000 cells/well. Scatter plots r present the parameters resulting of WimTube analysis:
total tubes, tot l bra ching poi ts and total loops (n = 12 for all groups, white scale bar = 500 µm);
(c) Graphs represe ting mRNA fold change expressi n of CDH5, ENG, EPHA2, KDR, LAMC2, TEK
and TIE1 in UM-2B WT and ATS1-KO cells (n = 3–5 for WT, n = 3–6 for ATS -KO1 and n = 2–4 for
ATS1-KO2); (d) Graph representing mRNA fold change expression of CDH5 in C8161 T -
cells ( f r all groups). ( *, p < .0001; **, p < .001; **, p < 0.01; and *, p < 0.05. WT cells were
u ed as control for statistic analyses).
2.3. ADAMTS1 Inhibition Affects In Vivo Tumor Progression and Vasculature
According to previous reports with MUM-2B cells [9], we first executed xenograft studies using
Swiss Nude (SwN) mice. Very significantly, all SwN mice injected with WT but none with ATS1-KO
cells developed tumors, corroborated even after sacrifice (Figure 3a,b and d). Although this robust
result already implied a key contribution of ADAMTS1, we applied the following conditions to confirm
it. We injected cells in a 1:1 PBS:Matrigel solution (SwN-Matrigel), reported to support initial cell
engraftment and subsequent tumor progression [22]. Under these conditions, ATS1-KO cells, although
inducing some tumors, still displayed lower efficiency than WT cells (Figure 3a). Indeed, progression
of ATS1-KO-derived tumors was clearly compromised in comparison with WT group (Figure 3b,d).
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experimental group (in parenthesis); (b) Graph representing final tumor weight of different 
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Figure 3. ADAMTS1 inh bition blocks tumorigenesis and alters tumo vasculature. (a) Tabl indicating
the number of mice that developed umors and the total number of injected mice of very exp rim ntal
group (in parenthesis); (b) Graph r presenting final tumor weight of different exp rimental groups,
according to panel A; ( ) Represent tive pictures of tumors from SwN-Matrigel and NSG groups
(black scale bar = 1 cm); (d) Graphs representing tumor evolutio for each experimental group.
(e) Representative images of EMCN immunofluorescence analysis of tumor sections from WT and
ATS1-KO NSG xenografts (white scale bar = 100 µm); (f) Graphs representing tumor vasculature
quantification of NSG xenografts: vessel density, vessel perimeter and percentage area (n = 5 for WT;
n = 7 for ATS1-KO1; n = 6 for ATS1-KO2). (***, p < 0.001 and **, p < 0.01. Tumors generated with WT
cells were used as control for statistical analyses).
Given the major blockade of tumor growth when ADAMTS1 was inhibited in these two models,
we were unable to get relevant biopsies of some experimental groups. Therefore, we pursued tumor
progression on NOD scid gamma (NSG) mice, expecting an increased tumor engraftment according to
the strongest failure of their immune system [23]. Certainly, now all the injected NSG mice developed
tumors (Figure 3a). However, again in accordance with previous results, the comparison of tumor
development by WT and ATS1-KO cells in NSG mice revealed significant differences in terms of tumor
weight and volume (Figure 3b,d).
All these data confirmed the relevance of ADAMTS1 for tumor development. Since previous
findings already remarked its effect on the vasculature [9,11,24], we analyzed it in our NSG samples.
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Endomucin (EMCN) IF revealed an increased vessel density but a reduction in perimeter in tumors
derived from ATS1-KO cells (Figure 3e,f), resulting in a lack of significant differences in terms of total
vessel area between WT and ATS1-KO tumors (Figure 3f), as previously described in other tumor
studies [6,9].
At this point, although vasculature displayed alterations, the blockade of tumor progression when
ADAMTS1 was inhibited is still unsolved. In line with the recognized plasticity of melanoma cells
and the putative role of ADAMTS1 in such phenomena [10], we decided to evaluate stemness-related
features in our tumors.
2.4. ADAMTS1 Inhibition Compromises Tumor Stemness and Plasticity Features
Taking advantage of the distinct origin of tumor (human) and stromal (murine) cells in our
xenografts, we approached the evaluation of stemness genes NANOG, POU5F1 (OCT4), PROM1
(CD133) and SOX2, from the tumor origin. Importantly, the analysis of WT tumors revealed a
significant upregulation of NANOG and POUF5F1 when compared with the original tumor cells
under 2D culture conditions (Figure 4a and Figure S2a), confirming the high impact of the tumor
microenvironment on promoting stemness. Interestingly, ADAMTS1 and CDH5 also appeared
significantly induced in the tumor context (Figure 4b,c, Figure S2b,c), suggesting again their direct link
during tumor progression.
In line with the impaired progression, ATS1-KO tumors showed an overall downregulation
of stemness markers compared with WT samples, especially significant for the more abundant
NANOG and POU5F1 (Figure 4d and Figure S2d). Moreover, in the same way that we observed a
significant alteration of endothelial genes in ATS1-KO cultured cells (Figure 2c), now ATS1-KO tumors
showed a chief reduction in CDH5 mRNA levels compared with WT samples (Figure 4e, and Figure
S2e). The contribution of CDH5 in the VM phenomenon has already been reported [25–27], so we
were interested in visualizing human CDH5 in our tumor histological sections by IF. The analysis
of WT tumors allowed the identification of a cell surface pattern for CDH5, noticeably associated
with tumor cells in the vicinity of EMCN-positive vascular niches (Figure 4f). Furthermore, this
pattern was more arduous to find in ATS1-KO tumors, and it was generally less consistent that in
WT samples. Therefore, according to the similar behavior of CDH5 and NANOG in our melanoma
culture model, we evaluated their relationship in tumor sections. As the co-staining was not
feasible, we performed IHC in sequential tumor sections (Figure 4g). In addition to the clearly
compromised NANOG positive staining in ATS1-KO tumors, we detected a spatial coincidence of
NANOG and CDH5 expression in WT samples that was difficult to appreciate in ATS1-KO sections.
Finally, we performed double CDH5-PAS immunostaining to check a similar spatial coincidence
between endothelial-related CDH5 and PAS-positive patterns, widely used as identifier of VM [13].
Certainly we observed such concurrence much better in WT than in ATS1-KO tumors, as well as a
significant increase in VM+ patterns in WT tumors (Figure 4h).
All these results suggested a close association between stemness and plasticity features that would
lead to VM events, so we evaluated such parameters back in tumor cells.
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xenografts (n = 4–6 for cells and n = 3–4 for NSG); (d-e) Graphs representing mRNA fold change
expression of NANOG, POU5F1, PROM1 and SOX2 (d), and CDH5 (e) in NSG xenografts generated with
WT and ATS1-KO cells (n = 3 for WT, n = 5 for ATS1-KO1 and n = 4–6 for ATS1-KO2); (f) Representative
images of IF analysis of WT and ATS1-KO NSG xenografts, at low and high magnification. For low
magnification, columns from left to right: CDH5, EMCN, DAPI and merge; (g) Representative images
of IHC staining of CDH5 and NANOG in consecutive sections of WT and ATS1-KO NSG xenografts;
(h) Representative images of IHC co-staining of CDH5 and PAS, in WT and ATS1-KO NSG xenografts.
(****, p < 0.0001; **, p < 0.01; and *, p < 0.05. White scale bar = 50 µm).
2.5. ADAMTS1 Inhibition Compromises In Vitro Stemness Capacities
Although stemness features have been attributed to melanoma, our evaluation of stemness genes
(NANOG, POU5F1, PROM1 and SOX2), revealed a very low expression among the tested cells on
2D culture. In agreement with the recognized induction of stemness properties, we approached the
melanoma sphere formation assay with MUM-2B cells. Furthermore, we evaluated the expression
levels of stemness genes in this material, as well as ADAMTS1 and CDH5, according to their relevance
suggested by our previous results. First, we confirmed a significant induction of stemness NANOG,
POU5F1 and PROM1 in the melanoma sphere formation process, in both primary and secondary WT
spheres (Figure 5a and Figure S3a). Importantly, we detected a significant induction of both ADAMTS1
and CDH5, implying again a role for these molecules in melanoma plasticity. With these premises,
we generated melanoma spheres with ATS1-KO cells. Remarkably, the absence of ADAMTS1 had a
dramatic effect by compromising the formation of both primary and secondary spheres (Figure 5b,c
and Figure S3b).
Given the strong impairment of ATS1-KO cells to form spheres, we evaluated gene expression
levels of NANOG and CDH5 in their primary spheres, according to their alteration in our tumor model.
Contrary to WT cells (Figure 5a), ATS1-KO spheres presented no significant changes in the expression
of these genes when comparing with 2D cultures (Figure 5d and Figure S3c). It was noteworthy that
the low levels of CDH5 that ATS1-KO cells displayed in 2D culture were not induced at all in the
process of sphere formation, as occurred with WT cells.
All these data demonstrated that ADAMTS1 inhibition also compromises stemness capacities
in MUM-2B UVM cells. According to the extracellular nature of ADAMTS1, we then evaluated if
medium containing this secreted protease could affect the sphere formation ability. First, we used CM
of MUM-2B cells (identified as ADAMTS1+ CM) (scheme in Figure 5e). Notably, this medium enhanced
the formation of spheres in both WT and ATS1-KO cells. Indeed, the size and number of spheres of
ATS1-KO cells with ADAMTS1+ CM was comparable to that of WT cells with normal CSC medium
(Figure 5f,g), suggesting that secreted ADAMTS1 have a positive effect on the recovery of stemness
capacities of MUM-2B cells. Second, according to the complex nature of the CM, we performed the
sphere assay using CSC medium with and without pure recombinant human ADAMTS1 (rhATS1).
Now this experiment revealed that rhATS1 in the medium did not affect WT sphere formation, but it
had a significant effect on the sphere formation of ATS1-KO1 cells, although still not reaching WT
properties (Figure 5h,i).
While our findings with melanoma spheres confirmed the implication of recognized stemness
markers, we were positively surprised that ADAMTS1 also appeared to be induced during the process
and, indeed, that its inhibition blocked the formation of spheres. Furthermore, the induction of
endothelial CDH5 in melanoma spheres revealed an unexpected link between melanoma stemness
features and its putative endothelial-like phenotypic properties, supporting the results obtained with
our tumor models.
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n = 62 for ATS1-KO1, and n = 58 for ATS1-KO2) and secondary (n = 46 for WT, n = 34 for ATS1-KO1 
and n = 21 for ATS1-KO2) melanoma spheres. WT spheres volume was used as control for statistical 
analyses; (c) Representative images of WT and ATS1-KO primary melanoma spheres grown in CSC 
medium; (d) Graphs representing mRNA fold-change expression of NANOG and CDH5 in 2D culture 
(n = 4–6 for ATS1-KO1 and n = 2–4 for ATS1-KO2) and primary melanoma spheres (n = 2 for ATS1-
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Figure 5. Inhibition of ADA TS1 co pro ises elano a sphere for ation. (a) Graphs representing
mRNA fold-change expression of NANOG, POU5F1, PRO 1, ADA TS1 and CDH5 in MUM-2B WT
2D culture, primary and secondary melanoma spheres (n = 4 for 2D culture, except for ADAMTS1
which is 12; n = 2–5 for primary spheres, and n = 4–6 for secondary spheres). 2D cultured cells were
used as control for statistical analyses; (b) Violin plots representing volume of primary (n = 49 for
WT, n = 62 for ATS1-KO1, and n = 58 for ATS1-KO2) and secondary (n = 46 for WT, n = 34 for
ATS1-KO1 and n = 21 for ATS1-KO2) melanoma spheres. WT spheres volume was used as control for
statistical analyses; (c) Representative images of WT and ATS1-KO primary melanoma spheres grown
in CSC medium; (d) Graphs representing mRNA fold-change expression of NANOG and CDH5 in 2D
culture (n = 4–6 for ATS1-KO1 and n = 2–4 for ATS1-KO2) and primary melanoma spheres (n = 2 for
ATS1-KO1 and n = 4–7 for ATS1-KO2). 2D cultured conditions were used as control for statistical
analyses; (e) Schematic protocol for melanoma spheres formation, using CSC medium and ADAMTS1+
CM; (f) Violin plots representing volume of WT and ATS1-KO primary melanoma spheres grown in
CSC medium (n = 49 for WT, n = 62 for ATS1-KO1, and n = 58 for ATS1-KO2) or in ADAMTS1+ CM
(n = 44 for WT, n = 48 for ATS1-KO1, and n = 49 for ATS1-KO2); (g) Representative images of WT
and ATS1-KO primary melanoma spheres in ADAMTS1+ CM; (h) Violin plots representing WT and
ATS1-KO1 primary melanoma spheres, grown in control CSC (n = 27 for WT, and n = 44 for ATS1-KO1)
or rhATS1+ CSC medium (n = 35 for WT, and n = 28 for ATS1-KO1); (i) Representative images of WT and
ATS1-KO1 primary melanoma spheres grown in control and rhATS1+ CSC medium. (****, p < 0.0001;
***, p < 0.001; **, p < 0.01; *, p < 0.05. Violin plots indicate the median of every experimental group.
White scale bar = 100 µm).
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2.6. Relevance of Endothelial-Like Plasticity in Human Uveal Melanoma
Consistent with the alterations of EL-related and stemness markers described above, all of
them modulated by ADAMTS1, we approached a close study of their contribution in human UVM.
Considering the infrequent nature of this tumor, the public availability of gene expression data in the
TCGA-UVM Project [28] allowed us to pursue such analyses in a relevant number of samples, including
prognosis parameters and staging classification. First, using the UCSC Xena platform, we found
that endothelial-related CDH5 and KDR appeared as significant poor prognosis factors (Figure 6a),
in full agreement with our experimental observations. Furthermore, the evaluation of co-expressing
genes across these cohorts of patients revealed a higher and significant correlation of CDH5 with
additional endothelial-related genes like CD34, TIE1, FLT4, KDR and COL4A1 (Figure 6b and Figure
S4), confirming the strong association of endothelial-related signature in this neoplasia. According to
the chief role of CDH5, we then approached a GO-enrichment analysis using the list of significantly
positive correlated genes with CDH5 (Table S4a, 1196 genes). This exploration revealed key features
such as ECM organization and the regulation of angiogenesis (Figure 6c and Table S4b), highlighting
the close and significant relationship between endothelium and matrix remodeling.
Then, taking into consideration the modulatory role that extracellular proteases exert on tumor
plasticity, we approached a whole evaluation of all members of the ADAMTS family of proteases,
noticing the strong similarity that exists among them at the structural and functional levels. In agreement
with the study of stemness markers, we did not find ADAMTS1 correlating with survival in UVM
patients, which was probably related with their role in initiating stages. Indeed, when we analyzed
ADAMTS1 expression data considering different stages of tumor progression, we observed a clear
tendency for ADAMTS1 to be more expressed at early phases (identified here with stage IIA) and
decreases with higher grades (Figure 6d). This higher expression at initial stages of UVM would
support our experimental data, as we observed a link between ADAMTS1 and stemness features,
closely related with tumor initiation and early UVM progression. Furthermore, it resulted quite
appealing the fact that up to six related family members displayed significant values as poor prognosis
factors for UVM, including the closer ADAMTS4, ADAMTS5 and ADAMTS9, but also others like
ADAMTS12, ADAMTS2 or ADAMTS14 (Figure 6e). Going back to ADAMTSs actions and CDH5
induction, we observed positive significant correlations between some of these proteases and CDH5
(Figure 6f), supporting the robust association between endothelial-like plasticity and ADAMTSs activity
favoring UVM progression.
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(n = 4 for IIA, n = 32 for IIB, n = 27 for IIIA, n = 10 for IIIB, n = 3 for IIIC and n = 4 for IV); (e) Kaplan–Meier
survival curves for low and high gene expression levels of extracellular proteases ADAMTS4, ADAMTS5,
ADAMTS9, ADAMTS12, ADAMTS2 and ADAMTS14; (f) Scatter plot representing Pearson correlation
analysis between gene expression levels of CDH5 and extracellular proteases ADAMTS4, ADAMTS9,
ADAMTS12 and ADAMTS2. (Survival probability is depicted in correlation analysis plots (panels
B and F) with light and dark red dots, representing low and high survival probability, respectively.
r = Pearson correlation coefficient).
3. Discussion
Tumor microenvironment (TME) remodeling is being recognized as a relevant contributor to
complex tumor heterogeneity, and one to be researched for a better understanding. To date, although
a number of extracellular proteases have been identified as possible therapeutic targets due to their
actions during tumor growth, their clinical use still requires much deeper investigation. In this work,
we first focused our attention on the impact of the extracellular protease ADAMTS1 on human uveal
melanoma (UVM), and particularly on its effects on cancer plasticity phenomena, revealing a new
relationship between intrinsic endothelial-like (EL) properties on tumor cells and their enrichment
on stemness features. A combination of experimental in vitro and in vivo approaches, together
with the use of bioinformatics methodologies on public tumor databases, allowed us to unveil the
unexplored relevance of endothelial-specific molecules, such as CDH5, strongly correlating with
ADAMTS proteases.
Our initial and comprehensive characterization of human uveal and skin melanoma cell lines
confirmed their heterogeneity but, more importantly, it supported their classification as EL+ or EL−.
Although based on experimental phenotypic properties, our bioinformatics approach using available
datasets of melanoma cell lines showed a clear connection with vascular functions as coagulation
and hemostasis. This approach also highlighted the contribution of endothelial CDH5 as a key
gene supporting our own data. While the literature has already shown the existence of differential
gene signatures among melanoma cell lines with different aggressiveness [15,29], our methodology
discriminated according to their behavior in the recognized Matrigel assay. In addition, we detected
ADAMTS1 to be significantly upregulated in EL+ cells. The absence of ADAMTS1 in our in silico
results, as also occurred with stemness related molecules, is probably linked with their low expression
levels, making them undetectable for microarray procedures.
Focusing on UVM, we succeeded in inhibiting ADAMTS1 in MUM-2B cells, and our subsequent
studies confirmed the disruption of relevant tumorigenic features. First, our Matrigel assays to
evaluate the EL phenotype showed that ATS1-KO cells were compromised in comparison with WT
cells. Moreover, we detected in these deficient cells a clear downregulation of EL markers, already
associated with VM and its aggressive phenotype in melanoma [15,27,30]. Notably, the performance
of xenograft assays in distinct mouse models supported the pro-tumorigenic effects of ADAMTS1 in
UVM, revealed mainly by the significant blockade of tumor development when ADAMTS1 was
inhibited. Indeed, our data with SwN mice disclosed a complete halt using ATS1-KO cells, which was
partially overcome using an NSG model. Importantly, the immune system of NSG mice displays a
stronger defect than SwN, so the distinct ability of ATS1-KO cells to initiate tumor progression in these
two models could be related with an immunomodulatory role already attributed to ADAMTS1 [11].
Certainly, these results encourage further studies to unveil the impact of this ECM-modifying enzyme
on the immune system, although distinct models must be considered.
Regarding the tumor vasculature, in agreement with previous reports [6,9], this current study also
showed evocative alterations although the overall vasculature appeared normalized. These observations
are aligned with the widely described role of some ADAMTSs as modulators of vasculature [24].
Nonetheless, additional actions of ADAMTS1 contribute to tumor development, at least in this setting.
Very importantly, we were able to match alterations of endothelial and stemness parameters. To our
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knowledge, this is the first time where a tumor displayed a clear correlation between the acquisition of
endothelial-like features and an intrinsic stemness signature, indeed correlating with the disruption
of tumorigenic properties. Our studies revealed an overall increase in stemness genes in tumors in
comparison to the original 2D cultures. Furthermore, we also found the EL marker CDH5 to be similarly
regulated. This intimate relationship between stemness, plasticity and the acquisition of EL properties,
both in vitro and in vivo, with everything modulated by the protease ADAMTS1, emphasizes the chief
contribution of ECM modifying enzymes. Suggestively, these results encourage the design of new and
improved specific inhibitors of matrix metalloproteases to overcome former disappointing results in
clinical trials [31]. Indeed, our results support a main involvement of CDH5-related pathways, but not
strictly from endothelial origins as originally hypothesized, according to their relevant expression in
plastic tumor cell populations.
Our assays involving the formation of tumor spheres also reinforced our findings. Although the
development of melanoma spheres from the MUM-2B cell line was already reported [32], to our
knowledge, this is the first work including a deeper description and characterization of the resulting
spheres. WT cells showed a clear upregulation of main stemness markers, together with the newly
reported induction of CDH5 and the protease ADAMTS1. While CDH5 has been already related with
stemness parameters [17,33,34] as a causal factor of vasculogenic mimicry events, our data exposed that
extracellular proteases such as ADAMTS1 should also been considered when studying the stemness
capacities or the aggressiveness of a tumor. In the case of ATS1-KO spheres, not only were they unable
to generate optimal spheres, but also, there were no significant changes to the expression of our genes
of interest. Importantly, our experiments using ADAMTS1-enriched media (secreted in the CM of
melanoma cells or as exogenous recombinant protein) supported the extracellular contribution of
this protease as a key factor for tumor initiation and growth, indeed corroborated by our in vivo
approaches. This role of ADAMTS1 during initiating stages of tumorigenesis possibly justifies its
absence in standard gene expression notations as we mentioned in our studies in cell lines and also in
human UVM samples.
According to the modest knowledge of UVM, considered a rare type of cancer with an estimated
incidence of 4.9–5.2 cases per million in the United States and a rate of 2–8 cases per million in
Europe [17], our new findings give strength to its recognized plastic nature. With the intention to
advance the fight against this type of melanoma, we conducted a deep study of genes of interest in
human UVM datasets from TCGA. Suggestively, we found that the endothelial-related genes CDH5
and KDR appeared as significant poor prognosis factors in these neoplasias. Although the fact that
CDH5 should be considered a poor prognosis gene is supported all along this work, we find it especially
interesting that other EL genes displayed similar features. Indeed, these genes were formerly related
with VM and stemness features [30,35], and our own experiments confirm such involvement.
Very importantly, the evaluation of ADAMTS1 in this tumor collection allowed us to observe its
higher expression levels at early phases of this malignant tumor, and then appeared downregulated
as the disease progressed to advanced stages, in harmony with our results on stemness features.
Indeed, it resulted quite appealing the fact that such positive association did occur with high expression
of other ADAMTS proteases (ADAMTS2, ADAMTS4, ADAMTS5, ADAMTS9, ADAMTS12 and
ADAMTS14) that definitively implied a key role of these proteases during melanoma progression.
We need to remark on the strong similarity among these members, perfectly complementary within
the highly complex scenario of the TME.
Our in vitro and in vivo findings expose a complex communication between the endothelial
phenotype, stemness features and ECM regulation, contributing to the final fate of the tumor.
More specifically, the requirement of ADAMTS1 for tumor progression in our mouse models,
its relationship with stemness and endothelial plasticity features, and its higher expression at earlier
stages of UVM, all support the role of ADAMTS1 as a pro-tumorigenic factor for this rare type of
tumor. Lastly, this association suggests the participation of key molecules at the cell-matrix and
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cell-cell boundary connecting the proteolytic action of ADAMTS proteases with transmembrane and
intracellular pathways, which full comprehension would help to define new therapeutic strategies.
4. Materials and Methods
4.1. Cell Culture and Generation of ADAMTS1-Knockout Cells
Uveal melanoma MUM-2B and MUM-2C, and skin melanoma C8161 cell lines were kindly
provided by Dr. Arjan W. Griffioen (VUmc, Amsterdam, The Netherlands); skin melanoma SK-MEL-28,
SK-MEL-103, SK-MEL-147 by Dr. Juan A. Recio (VHIR, Barcelona, Spain); A-375 and G-361 by Dr.
Javier Oliver (IPBLN-CSIC, Granada, Spain); and HEK293T by Dr. Pablo Menéndez (IJC, Barcelona,
Spain). All cell lines were cultured in the appropriate medium supplemented with 10% fetal bovine
serum (Gibco) and 1% Penicillin/Streptomycin solution (Biowest, Nuaillé, France), under standard
conditions (37 ◦C, 5% CO2 and 95% relative humidity). Specific media were: RPMI 1640 with stable
glutamine (Biowest, Nuaillé, France) for MUM-2B, MUM-2C and C8161; High Glucose Dulbecco’s
Modified Eagle Medium (DMEM) with stable glutamine and sodium pyruvate (Biowest, Nuaillé,
France) for A-375, G-361, SK-MEL-28, SK-MEL-103, SK-MEL-147 and HEK293T. All cell lines were
routinely tested for Mycoplasma (Venor®GeM qEP, Minerva Biolabs, Berlin, Germany). MUM-2B cell
line was authenticated by STR Profiling (AmpFLSTR® Identifiler® Plus, Applied Biosystems, Waltham,
MA, USA).
The generation of ATS1-KO cells with lentivirus-based CRISPR-Cas9 system has been
described [36]. Two clonal populations were obtained from MUM-2B cell line (named ATS1-KO1 and
ATS1-KO2) and other two from C8161 (named ATS1-KO3 and ATS1-KO4), after two weeks of selection
(0.25 µg/mL Puromycin), and single cell cloning isolation and expansion processes. They were subjected
to Sanger DNA sequencing (primer sequences in Table S1) and Western blot analysis to confirm gene
edition and inhibition, respectively.
4.2. In Vitro 3D Matrigel-Based Assay
35 µL/well of Matrigel (Corning, Corning, NY, USA) were dispensed in a 96-well plate kept on
ice to avoid gelling. After Matrigel gelling, 100 µL of serum-free medium were added to each well.
Finally, 100 µL of serum-free medium containing cells (20,000–30,000 cells) were added. Follow-up was
performed taking pictures at various time points (Axio Vert microscope, A-Plan 5x/0.12 objective, Zeiss,
Oberkochen, Germany). If appropriate, 24 h pictures were subjected to WimTube analysis (Wimasis,
Córdoba, Spain) as indicated [37].
4.3. Tumor Xenograft Assays
Female Swiss Nude (SwN) and NOD scid gamma (NSG) mice were purchased from Charles River
Laboratories and housed at CIBM-UGR animal facility according to institutional guidelines (Approved
Ethical Committee #152-CEEA-OH-2016). For xenograft generation, 1 × 106 cells in 100 µL PBS were
subcutaneously injected in the flank of 6-weeks old mice. When using Matrigel as scaffold, 2 × 106
cells in a 150 µL PBS:Matrigel dilution (1:1) were subcutaneously injected in the flank of 16-weeks old
SwN mice. Animals were monitored every two days after cell injection until final time point, when
they were sacrificed and tumors were dissected for further analyses. Tumor volume was calculated
as: in progress tumor volume = (π × length × width2)/6, and final tumor volume = (π × length × width ×
height)/6) [11].
4.4. Vasculature Characterization and Immunohistochemistry
For the morphometric analysis of vasculature, tumor paraffin sections were subjected to
immunofluorescence (IF) with a rat anti-mouse EMCN (endomucin) antibody (V.7C7, SC-65495,
SCBT) and Alexa Fluor 488 donkey anti-rat secondary antibody (A21208, ThermoFisher Scientific,
Waltham, MA, USA). IF images were captured (Axio Imager A.1 microscope, EC Plan-Neofluar
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10x/0.30 Ph 1 objective, AxioCam MR R3, Zeiss, Oberkochen, Germany) and converted to binary for
further analysis as indicated [9]. CDH5 and NANOG were detected with rabbit anti-human CDH5
(160840, Cayman Chemical, Ann Arbor, MI, USA) or NANOG (4903, Cell Signaling Technology, Danvers,
MA, USA) antibodies, respectively. Alexa Fluor 647 goat anti-rabbit (A-21245, ThermoFisher Scientific,
Waltham, MA, USA), and Dako EnvisionTM + System-HRP (DAB) (K4010, Agilent Technologies,
Santa Clara, CA, USA) were used as secondary antibodies. Antigen retrieval was performed by slide
immersion in Tris-HCl 0.5 M pH = 10 solution and 10 min boiling. DAPI (D8417, Sigma-Aldrich,
St. Louis, MO, USA) solution and Dako Mayer’s Hematoxylin (S3309, Agilent Technologies, Santa
Clara, CA, USA) were used for nuclear counterstain in IF and IHC, respectively. Antifade Mowiol
(81381, Sigma-Aldrich, St. Louis, MO, USA)-DABCO (D27802, Sigma-Aldrich, St. Louis, MO, USA, St.
Louis, MO, USA) mixture and D.P.X. (317616, Sigma-Aldrich) were used as mounting media for IF
and IHC, respectively. PAS staining was performed with Periodic acid solution (3951, Sigma-Aldrich,
St. Louis, MO, USA) and Schiff’s reagent (3952016, Sigma-Aldrich). Confocal images were captured
with a LSM 710 Axio Observer (Plan-Apochromat 63x/1.4 Oil DIC M27 objective, Zeiss, Oberkochen,
Germany). IHC images were captured with a BX43 microscope (Plan-Achromat 20x/0.4 objective,
Olympus, Tokyo, Japan).
4.5. Melanoma Sphere Formation Assay
5000 cells/mL were seeded in non-adherent bacterial plates with CSC medium (DMEM-F12 without
L-Glutamine nor Hepes (Biowest, Nuaillé, France) supplemented with 1% Penicillin/Streptomycin
(Biowest, Nuaillé, France), B-27™ (40 mL/L, ThermoFisher Scientific, Waltham, MA, USA), human FGF-2
(0.01 µg/mL, Miltenyi Biotec, Bergisch Gladbach, Germany) and human EGF (0.02 µg/mL, Miltenyi
Biotec, Bergisch Gladbach, Germany). Medium was renewed weekly by low speed centrifugation
(5 min, 800 rpm) until primary spheres were obtained after 3 weeks. To generate secondary spheres,
primary spheres were disaggregated through a 29G needle and seeded again at a density of 5000 cells/mL
in 60 mm suspension culture dishes (Corning, Corning, NY, USA). For assays using recombinant
human ADAMTS1 (rhATS1, 2197-AD, R&D), spheres were grown in 6-well ultralow attachment plates
(Corning, Corning, NY, USA), using CSC medium supplemented with 1 µg/mL rhATS1. For assays
using conditioned medium (CM), fresh medium was collected from 24 h cultured MUM-2B cells and
supplemented with B-27, FGF-2 and EGF as described above. Images were captured with an Axio
Vert microscope (A-Plan 5x/0.12 objective, Zeiss, Oberkochen, Germany), and evaluated with Carl
Zeiss ZEN 2.3 SP1 (black) software (Oberkochen, Germany). Sphere volume was calculated as: sphere
volume = (π × length × width2)/6.
4.6. RNA Isolation and Quantitative RT-PCR
RNA was extracted with NucleoSpin®RNA kit (Macherey-Nagel, Duren, Germany) and reverse
transcribed with iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). qPCR reactions were
performed with Fast SYBR™ Green Master Mix (Applied Biosystems, Waltham, MA, USA), using
7900HT Fast Real-Time PCR (Applied Biosystems, Waltham, MA, USA) and QuantStudio 6 Flex
Real-Time PCR (Applied Biosystems, Waltham, MA, USA) platforms. ACTB, B2M and RNA18S1 were
used as housekeeping genes, depending on the sample origin and the platform (primer sequences in
Table S1).
4.7. Western Blot Analysis
Secreted proteins were obtained from CM of melanoma cells cultured over 24 h in the absence of
serum, and concentrated with StrataClean resin (Agilent Technologies, Santa Clara, CA, USA) [38].
Total protein from cell lysates was extracted with RIPA buffer (containing 10 µg/mL aprotinin, 1 mM
PMSF and 100 µM leupeptin) and quantified with Pierce BCA Protein Assay Kit (ThermoFisher,
Waltham, MA, USA) in an Infinite 200 PRO NanoQuant (Tecan, Männedorf, Switzerland) absorbance
reader. All samples (CM from cells cultured in a 100 mm dish, and 30 µg of cell lysate) were resolved
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by SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). Membranes were
stained with a Red Ponceau solution to visualize loaded proteins. Then, membranes were blocked with
5% low-fat milk and incubated with sheep anti-human ADAMTS1 (AF5867, R&D Systems, Minneapolis,
MN, USA) and monoclonal mouse anti-Actin (sc-8432, Santa Cruz Biotechnology, Dallas, TX, USA)
antibodies. After incubation with HRP-conjugated secondary antibodies (HAF016, R&D Systems,
Minneapolis, MN, USA), signal was detected with the ECL Prime Western Blotting Detection Reagent
(GE Healthcare Life Sciences, Marlborough, MA, USA) in an ImageQuant LAS4000 (GE Healthcare
Life Sciences, Marlborough, MA, USA).
4.8. Bioinformatic Analyses of Cell Lines Datasets and Melanoma Patients
NCBI Gene Expression Omnibus [39] was mined to find optimal datasets of melanoma cell lines
used in this study plus human umbilical vein endothelial cells (HUVECs), yielding a total of 31 samples
from 13 different datasets (Table S2). Gene expression data were downloaded, probe identifiers were
annotated with gene symbols and median gene expression values were calculated for duplicated
genes and rank normalized to allow sample comparisons from different technologies. Linear models
implemented in limma R package [40] allowed us to analyze differential gene expression between
groups of cell lines. Genes were selected by false discovery rate (FDR) < 0.05. A combination of
clusterProfiler [41] and REViGO [42] were used to evaluate representative enriched GO biological
processes, selecting GO terms showing an adjusted p-value < 0.05.
Genomic Data Commons TCGA Uveal Melanoma Project (TCGA-UVM) [28,43] and UCSC Xena
platform [44] were used to obtain survival and gene expression data from patients. Kaplan–Meier
curves were obtained comparing patients with low (quartile 1 [Q1]) and high (above quartile 3 [Q3])
gene expression levels. Pearson correlation analyses were performed using the list of genes that
positively correlate with CDH5 using cBioPortal platform [45,46], and comparing normalized gene
expression levels from Xena platform. Gene expression data were shown as Fragments Per Kilobase of
transcript per Million mapped reads upper quartile (FPKM-UQ).
4.9. Statistical Analysis
Statistical analyses were made with GraphPad Prism 8 (GraphPad software Inc., San Diego, CA,
USA). Except when indicated, graphs represent mean ± SEM, and unpaired t tests were performed to
compare means of two experimental groups. Robust regression and Outlier removal (ROUT) method
was applied to identify outliers when necessary. For qPCR analysis, values of ∆∆Ct out of mean ± SD
were considered as outliers, as well as values of Ct that were lower than Q1 − 1.5 × IQR (interquartile
range) or greater than Q3 + 1.5 × IQR.
5. Conclusions
In this work, we find that the inhibition of the extracellular protease ADAMTS1 alters the
endothelial-like properties of uveal melanoma cells in vitro and affects tumor vasculature in vivo.
Indeed, our experiments show that ADAMTS1 is also relevant to the stemness capacities of such
tumor cells in both in vitro and in vitro approaches, with strong consequences for tumor growth.
The inhibition of this protease reveals a new link between stemness and endothelial-like features
of uveal melanoma cells, and the evaluation of gene expression data of human samples shows its
relevance at early stages, also implying the contribution of further ADAMTS members during more
advance stages.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/4/801/s1,
Figure S1: ADAMTS1 expression in human melanoma cell lines and effect of its edition on in vitro EL phenotypic
properties; Figure S2: ADAMTS1 inhibition compromises the expression of stemness and EL related genes in
tumor xenografts; Figure S3: ADAMTS1 inhibition compromises formation of secondary melanoma spheres;
Figure S4: Positive correlation of additional endothelial genes with CDH5; Table S1: Sequences of used primers
for genes of interest; Table S2: Public gene expression datasets; Table S3A-B: Differently-expressed genes between
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EL+ and EL− cells and GO enrichment analysis of upregulated genes in EL+ cells; Table S4A-B: Genes positively
correlated with CDH5 and GO enrichment analysis.
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